BR112016028192A2 - gerritdina g. schoonus-gerritsma - Google Patents

gerritdina g. schoonus-gerritsma

Info

Publication number
BR112016028192A2
BR112016028192A2 BR112016028192A BR112016028192A BR112016028192A2 BR 112016028192 A2 BR112016028192 A2 BR 112016028192A2 BR 112016028192 A BR112016028192 A BR 112016028192A BR 112016028192 A BR112016028192 A BR 112016028192A BR 112016028192 A2 BR112016028192 A2 BR 112016028192A2
Authority
BR
Brazil
Prior art keywords
schoonus
gerritdin
gerritsma
pharmaceutical formulations
stable pharmaceutical
Prior art date
Application number
BR112016028192A
Other languages
English (en)
Inventor
G Schoonus-Gerritsma Gerritdina
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP14172805 priority Critical
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Priority to PCT/EP2015/063292 priority patent/WO2015193224A1/en
Publication of BR112016028192A2 publication Critical patent/BR112016028192A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Abstract

a presente invenção refere-se às formulações farmacêuticas estáveis. mais especificamente, a presente invenção refere-se às formulações farmacêuticas estáveis de undecanoato de testosterona.
BR112016028192A 2014-06-17 2015-06-15 gerritdina g. schoonus-gerritsma BR112016028192A2 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP14172805 2014-06-17
PCT/EP2015/063292 WO2015193224A1 (en) 2014-06-17 2015-06-15 Stable formulations of testosterone undecanoate

Publications (1)

Publication Number Publication Date
BR112016028192A2 true BR112016028192A2 (pt) 2017-08-22

Family

ID=50980940

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028192A BR112016028192A2 (pt) 2014-06-17 2015-06-15 gerritdina g. schoonus-gerritsma

Country Status (12)

Country Link
US (1) US9925200B2 (pt)
EP (1) EP3157505B1 (pt)
JP (1) JP6618488B2 (pt)
KR (1) KR20170020779A (pt)
CN (1) CN106456782B (pt)
AU (1) AU2015276321B2 (pt)
BR (1) BR112016028192A2 (pt)
CA (1) CA2950670A1 (pt)
ES (1) ES2749008T3 (pt)
MX (1) MX2016016612A (pt)
RU (1) RU2708238C2 (pt)
WO (1) WO2015193224A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019102040A1 (en) 2017-11-27 2019-05-31 Umecrine Cognition Ab PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189235C (nl) 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
US4147783A (en) 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
US4098802A (en) 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
NL7510104A (nl) 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
WO1991002520A1 (en) 1989-08-17 1991-03-07 Cortecs Limited Pharmaceutical formulations
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
RU2211021C2 (ru) 1997-07-29 2003-08-27 Фармация Энд Апджон Компани Фармацевтическая самоэмульгирующая композиция и ее носитель для липофильных фармацевтически активных агентов
US7396526B1 (en) * 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
TR200102769T2 (tr) 1999-04-01 2002-05-21 Akzo Nobel N.V. Testosteron undekanoat ve hint yağı ihtiva eden formülasyon
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
RU2303981C2 (ru) * 2000-11-01 2007-08-10 Юнимед Фармасьютикалс, Инк. Способ лечения эректильной дисфункции и повышения либидо у мужчин
US20070298099A1 (en) * 2004-11-24 2007-12-27 Peresypkin Andrey V Liquid and Semi-Solid Pharmaceutical Formulations for Oral Administration of a Substituted Amide
RU2429850C2 (ru) 2005-04-15 2011-09-27 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
EP2519230B1 (en) * 2009-12-31 2018-10-10 Marius Pharmaceuticals LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
NZ602821A (en) * 2010-04-12 2014-07-25 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120135074A1 (en) * 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
CA2905703A1 (en) 2013-03-15 2014-09-18 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US10245273B2 (en) 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents

Also Published As

Publication number Publication date
AU2015276321A1 (en) 2016-11-10
MX2016016612A (es) 2017-03-20
ES2749008T3 (es) 2020-03-18
WO2015193224A1 (en) 2015-12-23
JP6618488B2 (ja) 2019-12-11
CN106456782B (zh) 2020-02-18
RU2017101240A3 (pt) 2019-02-22
JP2017522283A (ja) 2017-08-10
RU2017101240A (ru) 2018-07-17
US20170136033A1 (en) 2017-05-18
EP3157505B1 (en) 2019-07-24
EP3157505A1 (en) 2017-04-26
CN106456782A (zh) 2017-02-22
AU2015276321B2 (en) 2019-10-24
KR20170020779A (ko) 2017-02-24
CA2950670A1 (en) 2015-12-23
US9925200B2 (en) 2018-03-27
RU2708238C2 (ru) 2019-12-05

Similar Documents

Publication Publication Date Title
IL249197D0 (en) Stable Cannabinoid Formulations
CL2016002455A1 (es) Anticuerpos multiespecíficos.
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
PH12016501151A1 (en) Nrf2 regulators
BR112017006137A2 (pt) formulação que contém biotensoativo
EP3302426A4 (en) D2o stabilized pharmaceutical formulations
BR112017004573A2 (pt) composições detergentes contendo um tensoativo ramificado
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
DOP2017000298A (es) Reguladores de nrf2
EP3099381A4 (en) Extended release fragrance compositions
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
BR112017027137A2 (pt) reguladores de nrf2
MX2015016755A (es) Reagrupamiento del virus de influenza.
IN2013MU03641A (pt)
BR112018007954A2 (pt) moduladores da interação sestrina-gator2 e usos destes
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
GT201600252A (es) Derivados de naftiridinadiona
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
GEP20217239B (en) Pharmaceutical composition
BR112017008854A2 (pt) partículas de cadotrila
IN2014CH00840A (pt)
GEP20217240B (en) Pharmaceutical composition
MX2016003207A (es) Composiciones que comprenden colina y derivados de esta, usos de las composiciones y procesos para su preparacion.
UY34595A (es) Composición farmacéutica de liberación prolongada de trimetazidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements